BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16622681)

  • 1. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.
    Alves PM; Faure O; Graff-Dubois S; Cornet S; Bolonakis I; Gross DA; Miconnet I; Chouaib S; Fizazi K; Soria JC; Lemonnier FA; Kosmatopoulos K
    Cancer Immunol Immunother; 2006 Dec; 55(12):1515-23. PubMed ID: 16622681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.
    Rodeberg DA; Nuss RA; Elsawa SF; Celis E
    Clin Cancer Res; 2005 Jun; 11(12):4545-52. PubMed ID: 15958640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.
    Alves PM; Faure O; Graff-Dubois S; Gross DA; Cornet S; Chouaib S; Miconnet I; Lemonnier FA; Kosmatopoulos K
    Cancer Res; 2003 Dec; 63(23):8476-80. PubMed ID: 14679012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
    Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
    PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
    Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
    Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
    Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
    J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.
    Hayashi S; Kumai T; Matsuda Y; Aoki N; Sato K; Kimura S; Kitada M; Tateno M; Celis E; Kobayashi H
    J Transl Med; 2011 Nov; 9():191. PubMed ID: 22053850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
    Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
    Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
    Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.
    Trojan A; Tun-Kyi A; Odermatt B; Nestle FO; Stahel RA
    Lung Cancer; 2002 May; 36(2):151-8. PubMed ID: 11955649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
    Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
    Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
    Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
    Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin.
    Nakatsugawa M; Horie K; Yoshikawa T; Shimomura M; Kikuchi Y; Sakemura N; Suzuki S; Nobuoka D; Hirohashi Y; Torigoe T; Harada K; Takasu H; Sato N; Nakatsura T
    Int J Oncol; 2011 Oct; 39(4):1041-9. PubMed ID: 21687943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.